Jeffrey J. Molldrem

The University of Texas MD Anderson Cancer Center — United States

Immunology and Microbiology · Life Sciences

56h-index12.8kcitations532works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(165), CAR-T cell therapy research(110), Acute Myeloid Leukemia Research(87), Hematopoietic Stem Cell Transplantation(76), Monoclonal and Polyclonal Antibodies Research(76)

Publications532 total

Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD
Blood Advances·2026Open Access
NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2025
Figure S2 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Figure S4 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Figure S1 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Figure S3 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Table S1-7 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
2025Open Access
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment
Cytotherapy·2025
LRP-1 regulates T cell proliferation and activation through global lipid network and loss of LRP-1 eliminates GVHD In Vivo
Blood·2025
Development of a novel LRP1 antibody that identifies upregulation of membrane LRP1 on activated and chimeric antigen receptor T cells
Blood·2025
Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant
Blood·2025
A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms
Blood·2025
Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy
Blood·2025
Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody
Blood·2025Open Access
TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells
Blood·2025
TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS
Blood·2025
1299 Tri-specific T cell engager (TCE) targeting cathepsin G peptide-HLA (pHLA) complex with enhanced antileukemic activity via proprietary CD28 co-stimulation
Regular and Young Investigator Award Abstracts·2025Open Access
1228 Immune escape through oncogene-mediated editing of the HLA-ligandome
Regular and Young Investigator Award Abstracts·2025Open Access
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
2025
page 1 of 27Next →

Frequent Co-authors

Richard E. Champlin(15), Elizabeth J. Shpall(10), Dimitriοs Mavroudis(8), Krishna V. Komanduri(8), Eric Wieder(8), Lisa S. St. John(7), Gheath Alatrash(6), Catherine M. Bollard(6), Marcos de Lima(6), Sergio Giralt(6), Ian McNiece(5), Chitra Hosing(5), A. John Barrett(5), Karen Clise-Dwyer(5), Qing Ma(5), Helen E. Heslop(4), Amin M. Alousi(4), John D. McMannis(4), Nina Shah(4), Muzaffar H. Qazilbash(4)